Solo Pace announced today that it received FDA clearance for its SoloPace Control System for temporary pacing in TAVR ...

Vivasure Medical®, a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced ...

Tariff talk will continue in the second week of earnings season, but the updates could also shed light on trends and ...

Solo Pace Incorporated, an emerging medical technology company, announced both FDA Clearance and First-In-Human use of their SoloPace Control System for temporary pacing in Transcatheter Aortic Valve ...

Vivasure Medical announced today that it received CE mark approval for its PerQseal Elite vascular closure system.

Thanks to healthcare reform, the hurdles to securing reimbursement and technology add-on payments have risen. Boston will need to invest more in clinical studies to demonstrate superiority of outcomes ...

The material is employed in a range of Edwards’ surgical and transcatheter valves, including versions of the Inspiris, Mitris ...

Vivasure Medical, an Ireland-based developer of fully absorbable technology for percutaneous vessel closure, announced ...

The 8-year data may hold value for TAVI—the newest Sapien valve uses the same tissue—but many other variables differ.

Adhering to the principles of evidence-based medicine, Venus Medtech has consistently conducted long-term follow-up studies ...

This week's topics include group A strep in the U.S., hearing loss and heart failure, a new medicine for multiple sclerosis, and making transcatheter aortic valve replacement outcomes better.